JPWO2022029617A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022029617A5 JPWO2022029617A5 JP2023507923A JP2023507923A JPWO2022029617A5 JP WO2022029617 A5 JPWO2022029617 A5 JP WO2022029617A5 JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023507923 A JP2023507923 A JP 2023507923A JP WO2022029617 A5 JPWO2022029617 A5 JP WO2022029617A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- halogen
- membered
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041033326 | 2020-08-04 | ||
| IN202041033326 | 2020-08-04 | ||
| PCT/IB2021/057089 WO2022029617A1 (en) | 2020-08-04 | 2021-08-03 | 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536504A JP2023536504A (ja) | 2023-08-25 |
| JP2023536504A5 JP2023536504A5 (https=) | 2024-08-09 |
| JPWO2022029617A5 true JPWO2022029617A5 (https=) | 2024-08-09 |
Family
ID=80117730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507923A Pending JP2023536504A (ja) | 2020-08-04 | 2021-08-03 | Ｓｍａｒｃａ２および／またはｓｍａｒｃａ４分解剤としての６置換ピリダジン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12570650B2 (https=) |
| EP (1) | EP4192835A4 (https=) |
| JP (1) | JP2023536504A (https=) |
| KR (1) | KR20230061349A (https=) |
| CN (1) | CN116529250A (https=) |
| AU (1) | AU2021320052A1 (https=) |
| BR (1) | BR112023002089A2 (https=) |
| CA (1) | CA3188024A1 (https=) |
| IL (1) | IL300387A (https=) |
| MX (1) | MX2023001445A (https=) |
| WO (1) | WO2022029617A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| WO2025196686A1 (en) * | 2024-03-20 | 2025-09-25 | Aurigene Oncology Limited | Fused bicyclic compounds as smarca2 and/or smarca4 degraders |
| CN119874808B (zh) * | 2025-01-02 | 2026-04-17 | 四川大学 | 一种靶向smarca蛋白降解的化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017518348A (ja) * | 2014-06-20 | 2017-07-06 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Ｉｒａｋ４阻害剤としての置換インダゾール化合物 |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017011371A1 (en) * | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Mdm2-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| KR20190140438A (ko) * | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | 암 치료를 위한 smarca2의 저해 |
| US20190300521A1 (en) | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US12371426B2 (en) | 2018-04-26 | 2025-07-29 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as SMARCA2/4 degraders |
| AU2021205326A1 (en) * | 2020-01-10 | 2022-07-21 | Amgen Inc. | SMARCA2-VHL degraders |
-
2021
- 2021-08-03 WO PCT/IB2021/057089 patent/WO2022029617A1/en not_active Ceased
- 2021-08-03 CN CN202180068383.4A patent/CN116529250A/zh active Pending
- 2021-08-03 AU AU2021320052A patent/AU2021320052A1/en active Pending
- 2021-08-03 US US18/019,721 patent/US12570650B2/en active Active
- 2021-08-03 IL IL300387A patent/IL300387A/en unknown
- 2021-08-03 CA CA3188024A patent/CA3188024A1/en active Pending
- 2021-08-03 BR BR112023002089A patent/BR112023002089A2/pt unknown
- 2021-08-03 MX MX2023001445A patent/MX2023001445A/es unknown
- 2021-08-03 KR KR1020237005345A patent/KR20230061349A/ko active Pending
- 2021-08-03 EP EP21852975.8A patent/EP4192835A4/en active Pending
- 2021-08-03 JP JP2023507923A patent/JP2023536504A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2468016C2 (ru) | СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl СО СВЯЗЫВАЮЩИМИ ПАРТНЕРАМИ | |
| JP2024099041A5 (https=) | ||
| JP7028809B2 (ja) | コルテキソロン１７α－バレレートを含む腫瘍治療に用いるための組成物 | |
| JP2019529444A5 (https=) | ||
| JP2021519783A5 (https=) | ||
| CN114430741A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JPWO2022029617A5 (https=) | ||
| JPWO2019191470A5 (https=) | ||
| CN106660974A (zh) | 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| CN119019382A (zh) | 取代的芳基或杂芳基并杂环烷基类抑制剂及其制备方法和应用 | |
| JP2020515571A5 (https=) | ||
| RU2009130599A (ru) | Лекарственные препараты для лечения рака | |
| WO2013044811A1 (zh) | 吉西他滨酰胺衍生物及其制备方法和用途 | |
| JPWO2021055295A5 (https=) | ||
| JP2017528416A5 (https=) | ||
| JP2019527239A5 (https=) | ||
| JPWO2021086785A5 (https=) | ||
| JP2020507624A5 (https=) | ||
| JP2018507230A5 (https=) | ||
| WO2012136133A1 (zh) | A-失碳-5α-雄甾烷化合物在制备抗恶性肿瘤药物中的应用 | |
| JP2023509385A (ja) | Ｅｚｈ２阻害剤の結晶性ヒドロブロミド塩、その調製及びがんの治療に有用な医薬組成物 | |
| CA2730079A1 (en) | Processes for the preparation of crystalline forms of sunitinib malate | |
| AU2020348825B2 (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof | |
| TW201139421A (en) | Novel ep4 agonist | |
| US20200009175A1 (en) | Nucleobase analogue derivatives and their applications |